GSK starts work on new pharmaceutical factory in India
When fully operational in 2017, the factory will make more than 8 billion tablets and 1 billion capsules in the areas of gastroenterology and anti-inflammatory medicines for the
Amberstone Biosciences has signed a partnership and licence agreement with Shanghai Henlius Biotech for conditionally activated T-cell engager candidates to treat solid tumours.
The analysis focused on identifying small molecule drug conjugate (SMDC) vintafolide in combination with docetaxel in patients with FR positive recurrent NSCLC. Endocyte said vintafolide plus docetaxel enhanced